Waldstein SM, et al. - In neovascular age-related macular degeneration, researchers studied the effect of posterior vitreous detachment (PVD) on the efficacy of treat-and-extend (T&E) ranibizumab. Spectral-domain optical coherence tomography images of treatment-naïve patients randomised to receive T&E (n = 265) or monthly (n = 264) ranibizumab for 12 months were involved in a post hoc analysis of a randomised controlled clinical trial. In 51% and 56% of patients in the monthly and T&E arms respectively, complete PVD was present at the baseline. Investigators found that in month 12, the mean change in BCVA was +9.0 (PVD) vs +9.5 letters (no PVD) in monthly treated eyes, and +6.0 (PVD) vs +7.5 letters (no PVD) in T&E treated eyes. In contrast, in month 12, the mean change in CRT was −174 (PVD) vs −173 µm (no PVD) in the monthly arm, and −175 (PVD) vs −164 µm (no PVD) in the T&E arm. The functional and anatomical results of T&E ranibizumab treatment have not been discovered to have an effect on PVD. Patients with no complete PVD, however, needed more retreatments and were considerably less likely to be extended effectively.